Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
Kurimoto C, Inaba H, Ariyasu H, Iwakura H, Ueda Y, Uraki S, Takeshima K, Furukawa Y, Morita S, Yamamoto Y, Yamashita S, Katsuda M, Hayata A, Akamatsu H, Jinnin M, Hara I, Yamaue H, Akamizu T. Kurimoto C, et al. Among authors: hayata a. Cancer Sci. 2020 May;111(5):1468-1477. doi: 10.1111/cas.14363. Epub 2020 Mar 17. Cancer Sci. 2020. PMID: 32086984 Free PMC article.
Progression of Irreversible Airflow Limitation in Asthma: Correlation with Severe Exacerbations.
Matsunaga K, Hirano T, Oka A, Tanaka A, Kanai K, Kikuchi T, Hayata A, Akamatsu H, Akamatsu K, Koh Y, Nakanishi M, Minakata Y, Yamamoto N. Matsunaga K, et al. Among authors: hayata a. J Allergy Clin Immunol Pract. 2015 Sep-Oct;3(5):759-64.e1. doi: 10.1016/j.jaip.2015.05.005. Epub 2015 Jun 6. J Allergy Clin Immunol Pract. 2015. PMID: 26054551 Clinical Trial.
Corrigendum to "Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab" [Lung Cancer 115 (2018) 71-74].
Sato K, Akamatsu H, Murakami E, Sasaki S, Kanai K, Hayata A, Tokudome N, Akamatsu K, Koh Y, Ueda H, Nakanishi M, Yamamoto N. Sato K, et al. Among authors: hayata a. Lung Cancer. 2018 Dec;126:230-231. doi: 10.1016/j.lungcan.2018.11.007. Epub 2018 Nov 18. Lung Cancer. 2018. PMID: 30459086 Free article. No abstract available.
Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer.
Akamatsu H, Murakami E, Oyanagi J, Shibaki R, Kaki T, Takase E, Tanaka M, Harutani Y, Yamagata N, Okuda Y, Furuta K, Sugimoto T, Teraoka S, Hayata A, Tokudome N, Ozawa Y, Mori K, Koh Y, Yamamoto N. Akamatsu H, et al. Among authors: hayata a. Oncologist. 2020 Apr;25(4):e679-e683. doi: 10.1634/theoncologist.2019-0299. Epub 2019 Nov 19. Oncologist. 2020. PMID: 32297443 Free PMC article.
CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small-cell lung cancer with PD-L1 tumor proportion score < 50.
Ozawa Y, Harutani Y, Oyanagi J, Akamatsu H, Murakami E, Shibaki R, Hayata A, Sugimoto T, Tanaka M, Takakura T, Furuta K, Okuda Y, Sato K, Teraoka S, Ueda H, Tokudome N, Kitamura Y, Fukuoka J, Nakanishi M, Koh Y, Yamamoto N. Ozawa Y, et al. Among authors: hayata a. Cancer Sci. 2021 Jan;112(1):72-80. doi: 10.1111/cas.14705. Epub 2020 Nov 27. Cancer Sci. 2021. PMID: 33084148 Free PMC article.
65 results